张志民

2017-06-23

张志民博士为乐土投资集团跨境投资董事总经理、乐土生命科技(深圳)总裁和CEO。乐土在生物科技、医疗器械和诊断、电子医疗、可穿戴设备、与生命科技相关的AR/VR和人工智能等领域投资,并帮助这些公司、项目和企业家在有需要时落地中国。我们的团队有丰富的经验,需要时可以为落地企业暂代CEO或高管等职,在帮助建设好他们自己的团队后适时退出。我们的投资架构非常灵活且根据合作伙伴的需要,比如股权投资、JV、技术授权、技术转让、生产、市场或者销售。我们在硅谷、纽约、波士顿、洛杉矶、上海、北京、深圳、广州、成都、武汉、廊坊、义乌都有团队。

张博士为前强生创新商务合作全球副总裁,负责强生三个事业部(医药部、医疗器械和诊断部、及消费品部)在亚太地区的创新商务合作及策略,并负责创新基金的关系和合作。之前,张博士是默沙东(美国默克制药公司)大中华区早期投资董事总经理,默沙东中国研发中心高层管理团队成员。负责美国默克在大中华区技术转让、并购及对外研发合作、联盟和合作伙伴的管理,以及风险投资。张博士曾任百济神州(BeiGene)董事和千骥资本(Cenova)指导委员会。

张博士原任美国协能基因控股集团资深副总裁。协能基因乃是美国生物技术先驱和奠基人之一的美国科学院院士William Rutter博士创建并领导的私募基金、投资控股公司和生物技术孵化加速器。协能基因投资的公司囊括生物制药、基因组工程、蛋白组工程、治疗性人源单抗、电子医药、医疗管理、营养医药、疫苗、蛋白药物制造、干细胞、临床诊断和医疗器械等领域。张博士曾任职于麦肯锡咨询公司;曾在世界领先的并担任北京奥运会组委会法律顾问的美国美富律师事务所(Morrison & Foerster) 的Palo Alto分所任注册专利代理人;在当时全美第二大生物技术公司Chiron公司(现为诺华制药) 担任项目经理。

张志民博士在南京大学获生物化学学士学位,在德克萨斯州大学达拉斯西南医学中心获生物医学博士学位,其间他从师三位诺贝尔奖获得者。在麻省理工学院斯隆管理学院攻读MBA期间,张博士当选为麻省理工学院 (MIT) 全校研究生总会的财务长。张博士是百华协会(BayHelix)的创始会员和前任董事会主席。

Dr. Jimmy Zhang is the managing director, cross-border investment at CL Investment Group, making investments in the fields of biotech, medical devices and diagnostics, digital health, wearables, and life sciences-related VR/AR and AI. When these companies, projects and entrepreneurs have needs to expand and localize into China, our broadly-experienced team will help them to land in China as a launch-pad by functioning as interim CEO and senior executives, and helping them to build their own management teams. Our deal structures are flexible: equity investment, JV, licensing, technology transfer, manufacturing, marketing and sales, etc., as fit by the partner.

 Jimmy was Vice President, Transactions, Johnson & Johnson Innovation.  He was responsible for transactional and partnership management activities and strategy in Asia Pacific region in pharmaceuticals, medical devices & diagnostics and consumer products, as well as fund relationship and partnership. He was the Managing Director, MSD Early Investments – Greater China at Merck & Co. He was responsible for Merck's venture capital investments, licensing, acquisitions, external research collaboration, and alliance/partnership management in Greater China. He was also a Board Director of BeiGene (Beijing) Co, Ltd. and an Advisor Board member of Cenova Ventures.

 Jimmy was Senior Vice President at Synergenics, LLC, a professional service and venture firm founded and led by Dr. Bill Rutter, one of the founding fathers and pioneers of the biotech industry. Synergenics invests and manages early-stage companies in drug discovery in small and large molecules, vaccine, gene therapy, diagnostics, and healthcare IT. Jimmy was previously a consultant at McKinsey, a registered patent agent at Morrison & Foerster, and a project manager at Chiron Corporation (now part of Novartis).

Jimmy received his B.S. in biochemistry from Nanjing University, and Ph.D. in biomedical sciences from University of Texas Southwestern Medical Center at Dallas, where he worked closely with three Nobel Laureates. While studying his MBA in MIT Sloan School of Management, Jimmy was elected as the treasurer of MIT Graduate Student Council. His MBA thesis in 2002 with Professor Rebecca Henderson was titled “Personalized Medicine: the Future of Medicine?” He was also a finalist of the 12th Annual MIT $50K Entrepreneurship Competition.

 Jimmy published in Cell, Nature, Neuron, and JBC, and holds multiple patents. Jimmy is a founding member and former Chairman of BayHelix Group, a prestigious non-profit organization of Chinese life sciences business leaders. Jimmy is also judges to State Thousand Talents Program and CHIC Business Plan Competition, a faculty member of Venture Capital Institute (China) and a guest professor at Tongji University.




上一篇:刘千叶
下一篇:杨志
Powered by 飞色网络